You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 17, 2024

Iobenguane i-131 - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for iobenguane i-131 and what is the scope of freedom to operate?

Iobenguane i-131 is the generic ingredient in one branded drug marketed by Progenics Pharms Inc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for iobenguane i-131
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 12
Clinical Trials: 16
Patent Applications: 180
What excipients (inactive ingredients) are in iobenguane i-131?iobenguane i-131 excipients list
DailyMed Link:iobenguane i-131 at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for iobenguane i-131
Generic Entry Date for iobenguane i-131*:
Constraining patent/regulatory exclusivity:
TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for iobenguane i-131

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jubilant DraxImage Inc.Phase 2
National Cancer Institute (NCI)Early Phase 1
Mayo ClinicEarly Phase 1

See all iobenguane i-131 clinical trials

US Patents and Regulatory Information for iobenguane i-131

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Progenics Pharms Inc AZEDRA iobenguane i-131 SOLUTION;INTRAVENOUS 209607-001 Jul 30, 2018 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.